Medivation Inc. (NASDAQ:MDVN)’s share price fell 0.4% during trading on Friday . The company traded as low as $62.32 and last traded at $62.51, with a volume of 472,217 shares traded. The stock had previously closed at $62.74.

A number of research firms recently commented on MDVN. Credit Suisse Group AG restated a “buy” rating on shares of Medivation in a report on Saturday, April 2nd. Cowen and Company restated a “hold” rating on shares of Medivation in a report on Sunday, April 17th. Wedbush restated a “buy” rating on shares of Medivation in a report on Saturday, April 30th. Stifel Nicolaus increased their price objective on Medivation from $52.00 to $66.00 and gave the stock a “buy” rating in a report on Monday, May 2nd. Finally, Barclays PLC restated a “buy” rating on shares of Medivation in a report on Sunday, May 8th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Medivation currently has a consensus rating of “Buy” and a consensus target price of $71.76.

The firm’s 50 day moving average price is $60.15 and its 200 day moving average price is $47.34. The firm has a market capitalization of $10.22 billion and a P/E ratio of 41.71.

Medivation (NASDAQ:MDVN) last posted its earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by $0.12. During the same quarter in the previous year, the firm earned $0.17 earnings per share. The company earned $182.50 million during the quarter, compared to analyst estimates of $197.01 million. The company’s revenue was up 41.3% compared to the same quarter last year. Equities research analysts predict that Medivation Inc. will post $1.30 EPS for the current year.

In related news, CFO Rick Bierly sold 10,340 shares of the business’s stock in a transaction on Friday, May 6th. The stock was sold at an average price of $59.76, for a total value of $617,918.40. Following the completion of the sale, the chief financial officer now directly owns 35,059 shares in the company, valued at approximately $2,095,125.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Andrew Kenneth William Powell sold 2,578 shares of the business’s stock in a transaction on Monday, June 6th. The shares were sold at an average price of $60.42, for a total value of $155,762.76. Following the completion of the sale, the senior vice president now owns 28,517 shares of the company’s stock, valued at $1,722,997.14. The disclosure for this sale can be found here.

Other hedge funds have recently added to or reduced their stakes in the company. American Century Companies Inc. increased its stake in Medivation by 0.8% in the fourth quarter. American Century Companies Inc. now owns 42,984 shares of the biopharmaceutical company’s stock valued at $2,078,000 after buying an additional 326 shares during the period. Neuberger Berman Group LLC purchased a new stake in Medivation during the fourth quarter valued at about $13,879,000. Bank of Montreal Can increased its stake in Medivation by 8.0% in the fourth quarter. Bank of Montreal Can now owns 38,138 shares of the biopharmaceutical company’s stock valued at $1,844,000 after buying an additional 2,836 shares during the period. Cornerstone Capital Management Holdings LLC. increased its stake in Medivation by 30.2% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 64,075 shares of the biopharmaceutical company’s stock valued at $3,098,000 after buying an additional 14,870 shares during the period. Finally, Tekla Capital Management LLC increased its stake in Medivation by 224.9% in the fourth quarter. Tekla Capital Management LLC now owns 667,300 shares of the biopharmaceutical company’s stock valued at $32,257,000 after buying an additional 461,900 shares during the period.

Medivation, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.